Article

Terapia celular em doenças pulmonares: existem perspectivas?

Revista Brasileira de Hematologia e Hemoterapia 01/2009; 31. DOI: 10.1590/S1516-84842009005000034

ABSTRACT SP. 4 Professor Colaborador da Disciplina de Hematologia e Hemoterapia da FMUSP-SP e coordenador do Grupo de Terapia Celular do IMC/HMC – São José do Rio Preto-SP. 5 Aluno(a) doPrograma de Pós-graduação em Biotecnologia da USP – São Paulo-SP. resulta-dos obtidos em modelos experimentais, é possível postular que a terapia celular com células-tronco hematopoéticas (ou de outras fontes) encerra perspectivas consistentes de aplicação em diversas outras patologias pulmonares humanas, especialmente em DPOC. Rev. Bras. Hematol. Hemoter. 2009;31(Supl. 1):140-148. Palavras-chave: Células-tronco; terapia celular; pulmão; doença pulmonar obstrutiva crônica (DPOC); enfisema; fibrose cística.

Download full-text

Full-text

Available from: João Tadeu Ribeiro-Paes, Jul 01, 2015
0 Followers
 · 
147 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Within the chronic obstructive pulmonary disease (COPD) spectrum, lung emphysema presents, as a primarily histopathologic feature, the destruction of pulmonary parenchyma and, accordingly, an increase in the airflow obstruction distal to the terminal bronchiole. Notwithstanding the significant advances in prevention and treatment of symptoms, no effective or curative therapy has been accomplished. In this context, cellular therapy with stem cells (SCs) arises as a new therapeutic approach, with a wide application potential. The purpose of this study is to evaluate the safety of SCs infusion procedure in patients with advanced COPD (stage IV dyspnea). After selection, patients underwent clinical examination and received granulocyte colony-stimulating factor, immediately prior to the bone marrow harvest. The bone marrow mononuclear cells (BMMC) were isolated and infused into a peripheral vein. The 12-month follow-up showed a significant improvement in the quality of life, as well as a clinical stable condition, which suggest a change in the natural process of the disease. Therefore, the proposed methodology in this study for BMMC cell therapy in sufferers of advanced COPD was demonstrated to be free of significant adverse effects. Although a larger sample and a greater follow-up period are needed, it is possible to infer that BMMC cell therapy introduces an unprecedented change in the course or in the natural history of emphysema, inhibiting or slowing the progression of disease. This clinical trial was registered with ClinicalTrials.gov (NCT01110252) and was approved by the Brazilian National Committee of Ethics in Research (registration no. 14764, CONEP report 233/2009).
    International Journal of COPD 01/2011; 6:63-71. DOI:10.2147/COPD.S15292
  • Source
    International Journal of COPD 01/2011;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Chronic Obstructive Pulmonary Disease (COPD) can be briefly described as air flow limitation and chronic dyspnea associated to an inflammatory response of the respiratory tract to noxious particles and gases. Its main feature is the obstruction of airflow and consequent chronic dyspnea. Despite recent advances, and the development of new therapeutic, medical and clinical approaches, a curative therapy is yet to be achieved. Therapies involving the use of tissue-specific or donor derived cells present a promising alternative in the treatment of degenerative diseases and injuries. Recent studies demonstrate that mesenchymal stem cells have the capacity to modulate immune responses in acute lung injury and pulmonary fibrosis in animal models, as well as in human patients. Due to these aspects, different groups raised the possibility that the stem cells from different sources, such as those found in bone marrow or adipose tissue, could act preventing the emphysematous lesion progression. In this paper, it is proposed a review of the current state of the art and future perspectives on the use of cell therapy in obstructive lung diseases.
    Stem cell reviews 10/2012; DOI:10.1007/s12015-012-9410-7